Advertisement

Drugs

, Volume 68, Supplement 1, pp 3–10 | Cite as

Trends in Kidney Transplantation over the Past Decade

  • Greg Knoll
Review Article

Abstract

Kidney transplantation offers patients with end-stage renal disease the greatest potential for increased longevity and enhanced quality of life; however, the demand for kidneys far exceeds the available supply. This has led to an increase in the number of people on waiting lists and an increase in waiting time. In the US, the overall median wait time was 2.85 years in 2004. The projected median waiting time for adult patients awaiting a deceased donor kidney in 2006 is 4.58 years. The renal transplant community has pursued multiple avenues in an attempt to increase the donor pool, but this remains a major challenge. In the last decade, the number of live donor kidney transplants performed in the US and Canada has doubled and represents just over 40% of all donor kidneys. Among deceased donor kidneys, the largest percentage increases were seen in expanded criteria donor and donation after cardiac death kidneys. In the last decade, the age distribution among donors, and among patients on waiting lists or receiving a renal transplant, has shifted towards older age groups. There have been dramatic shifts in baseline immunosuppression with increased usage of induction agents and the nearly universal replacement of azathioprine by mycophenolate. Additionally, tacrolimus use has increased from 13% to 79% at discharge, while ciclosporin (cyclosporine) use has fallen from 76% to 15%. Although 1-year graft survival rates are excellent, only modest improvements have been observed in long-term graft survival rates in the last decade. Thus, efforts have shifted from improving early graft outcomes to altering the natural course of late graft failure. Death of transplant recipients from cardiovascular disease, infection and cancer remains an important limitation in kidney transplantation. Continued success in kidney transplantation will require increased numbers of donors, both living and deceased, as well as reduction in the primary causes of late transplant loss, namely premature patient death with a functioning graft and chronic allograft nephropathy.

Keywords

Sirolimus Kidney Transplant Recipient Donor Kidney Deceased Donor Chronic Allograft Nephropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The author would like to thank Dr Cathryn Jarvis, Dr Isabella Steffensen and Science & Medicine Canada for assistance with this manuscript. The preparation of this manuscript was supported by an unrestricted grant from Wyeth Canada. Dr Knoll has received honoraria and participated in clinical trials funded by Astellas, Novartis and Wyeth.

References

  1. 1.
    Grassmann A, Gioberge S, Moeller S, et al. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005 Dec; 20(12): 2587–93PubMedCrossRefGoogle Scholar
  2. 2.
    Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1992 Dec 2; 341(23): 1725–30CrossRefGoogle Scholar
  3. 3.
    U.S. Renal Data System, USRDS 2006 Annual Data Report. Atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006 [online]. Available from URL: http://www.usrds.org/adr.htm [Accessed 2007 May 10]
  4. 4.
    Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996 Jul; 50(1): 235–42PubMedCrossRefGoogle Scholar
  5. 5.
    Canadian Organ Replacement Register (CORR), 2005. e-Statistics report on transplant, waiting list and donor statistics. 2005 summary statistics, January 1 to December 31, 2005. Ottawa: The Society; 2005 [online]. Available from URL: http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=reports_corrstats2005c_e [Accessed 2007 Feb 2]
  6. 6.
    Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients (OPTN/SRTR), 2006. 2006 OPTN/SRTR Annual Report. The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [online]. Available from URL: http://www.ustransplant.org/annual_reports/current/default.htm [Accessed 2007 Mar 6]
  7. 7.
    UNOS. Organ distribution: allocation of deceased kidneys. UNOS Policy 3.5.1. Definition of expanded criteria donor and standard donor. Richmond (VA): United Network for Organ Sharing, 2006 [online]. Available from URL: http://www.unos.org [Accessed 2007 Sep 14]
  8. 8.
    Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [OPTN/SRTR], 2005. 2005 OPTN/SRTR Annual Report. The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [online]. Available from URL: http://www.ustransplant.org/annual_reports/current/default.htm [Accessed 2007 Jan 6]
  9. 9.
    Lunsford SL, Simpson KS, Chavin KD, et al. Racial disparities in living kidney donation: is there a lack of willing donors or an excess of medically unsuitable candidates? Transplantation 2006; 82(7): 876–81PubMedCrossRefGoogle Scholar
  10. 10.
    Meier-Kriesche HU, Schold JD, Gaston RS, et al. Kidneys from deceased donors: maximizing the value of a scarce resource. Am J Transplant 2005 Jul; 5(7): 1725–30PubMedCrossRefGoogle Scholar
  11. 11.
    Ojo AO. Expanded criteria donors: process and outcomes. Semin Dial 2005 Nov–Dec; 18(6): 463–8PubMedCrossRefGoogle Scholar
  12. 12.
    Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006 Apr; 19(2): CD004290Google Scholar
  13. 13.
    Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/ sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007 Mar; 7(3): 586–94PubMedCrossRefGoogle Scholar
  14. 14.
    Adams PL. Long-term patient survival: strategies to improve overall health. Am J Kidney Dis 2006 Apr; 47 (4 Suppl. 2): S65–85PubMedCrossRefGoogle Scholar
  15. 15.
    Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004 Jun; 4(6): 905–13PubMedCrossRefGoogle Scholar
  16. 16.
    Kasiske BL, Israni AK. Strategies to prevent ischemic heart disease after kidney transplantation. Transplant Rev 2006 Jan; 20(1): 19–27CrossRefGoogle Scholar
  17. 17.
    Holdaas H, Fellstrom B, Jardine AG, et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003 Jun 14; 361(9374): 2024–31Google Scholar
  18. 18.
    Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006 Dec 20; 296(23): 2823–31PubMedCrossRefGoogle Scholar
  19. 19.
    Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005 Oct 15; 80 (2 Suppl.): S254–64PubMedCrossRefGoogle Scholar
  20. 20.
    Andrassy J, Graeb C, Rentsch M, et al. mTOR inhibition and its effect on cancer in transplantation. Transplantation 2005 Sep 27; 80 (1 Suppl.): S171–4PubMedCrossRefGoogle Scholar
  21. 21.
    Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002 May 27; 73(10): 1565–72PubMedCrossRefGoogle Scholar
  22. 22.
    Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002 Feb; 8(2): 128–35PubMedCrossRefGoogle Scholar
  23. 23.
    Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 2004 Mar 15; 77(5): 760–2PubMedCrossRefGoogle Scholar
  24. 24.
    Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005 Mar 31; 352(13): 1317–23PubMedCrossRefGoogle Scholar
  25. 25.
    Garcia VD, Bonamigo Filho JL, Neumann J, et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003 Mar; 16(3): 202–6PubMedCrossRefGoogle Scholar
  26. 26.
    Sierka K, Kumar MSA, Heifets M, et al. Successful minimization of immunosuppression (IM) and conversion to sirolimus (SLR) in kidney transplants recipients with post transplant lymphoproliferative disease (PTLD) and de novo nonskin malignancies (DNSM) [abstract no. 1331]. Am J Transplant 2004 Mar; 4 Suppl. 8: 523Google Scholar
  27. 27.
    Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004 Aug; 18(4): 446–9PubMedCrossRefGoogle Scholar
  28. 28.
    Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005 Sep 27; 80(6): 749–58PubMedCrossRefGoogle Scholar
  29. 29.
    Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 Feb; 17(2): 581–9PubMedCrossRefGoogle Scholar
  30. 30.
    Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 Oct 15; 80(7): 883–9PubMedCrossRefGoogle Scholar
  31. 31.
    Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 Mar 1; 22(5): 909–18PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Division of NephrologyUniversity of OttawaOttawaCanada
  2. 2.Ottawa Health Research InstituteOttawaCanada

Personalised recommendations